Products
Ambroxol is commercially available in the form of lozenges, sustained-release capsules, and syrup (e.g., Mucosolvon), among others. It has been approved in many countries since 1982.
Structure and properties
Ambroxol (C13H18Br2N2O, Mr = 378.1 g/mol) is present in drugs as ambroxol hydrochloride, a white to yellowish crystalline powder that is sparingly soluble in water. Ambroxol is a metabolite of bromhexine (bisolvone), which is itself derived from vasicin, a plant constituent from the Indian lungwort.
Effects
Ambroxol (ATC R05CB06) has local anesthetic, expectorant, expectorant, anti-inflammatory, and antioxidant properties.
Indications
- For the treatment of sore throat.
- Acute respiratory diseases with impaired secretion, especially in acute exacerbation of chronic bronchitis, asthmoid bronchitis, bronchial asthma and bronchiectasis.
Dosage
According to the professional information. The application depends on the drug.
Contraindications
- Hypersensitivity
- Severe renal or hepatic insufficiency
- Chronic disturbance of secretion production or clearance.
For complete precautions, see the drug label.
Interactions
Antitussives such as codeine or dextromethorphan prevent expectoration of liquefied bronchial mucus and should not be administered concomitantly. Ambroxol increases the concentration of the antibiotics amoxicillin, cefuroxime, and erythromycin in bronchial secretions and sputum.
Adverse effects
The most common potential adverse effects include gastrointestinal disturbances and nausea.
